28 JUL 2020: Independence, OH – Great Lakes NeuroTechnologies (GLNT) announced today that it received notices of allowance for four US patents related to movement disorder monitoring and therapy adjustment. These patents will expand GLNT’s patent portfolio of over 30 issued U.S. patents covering its proprietary technology. The four patents are expected to issue in late summer 2020.
GLNT commercialized Kinesia™ technology [ http://www.glneurotech.com/kinesia ] to provide wearable, objective and automated assessment of movement disorder such as Parkinson’s disease (PD) and essential tremor (ET). The clinically validated technology has been adopted as the gold-standard for objective sensor measurement for movement disorders by many of the world’s leading pharmaceutical and medical device companies. Last year, GLNT released the KinesiaU™ motor assessment system [ http://www.kinesiau.com ] , a prescription app that allows individuals to measure their Parkinson’s disease symptoms at home using consumer smartwatches and share their data remotely with their doctors.
According to GLNT President and COO, Dustin Heldman, Ph.D., “Since its founding ten years ago, GLNT has been the leader in remote patient monitoring for movement disorders. These four new patents will ensure our ability to provide real-world evidence and continue to expand our technology as an integral part of movement disorders therapy.” The newly allowed patents are summarized below.
2. US patent application 15/828,963 (Parkinson’s disease drug or medication titration, delivery system and method) covers radio frequency transmission of data from sensors to score various movement disorders. This could include for example the use of a smartwatch with a smart phone, or sensors where the data is scored with algorithms in the cloud.
3. US patent application 15/847,970 (Movement disorder continuous monitoring and therapy system) covers objectively looking at a patient’s movement disorder symptoms including dyskinesia, gait and balance disturbances, bradykinesia, rigidity, rest tremor, postural tremor and kinetic tremor during activities of daily living for adjusting advanced therapies such as deep brain stimulation (DBS) and drug pumps, and for following a patient’s disease state to provide feedback to the clinician or patient.
4. US patent application 15/847,974 (Parkinson’s disease drug or medication titration, delivery system, and method) covers technology for objectively displaying a patient’s disease state and using such disease state measurements for clinician reports or to adjust advanced therapies such as DBS and drug pumps used to treat the patient’s movement disorder.
Executive VP Brian Kolkowski, who leads GLNT’s business development, stated: “These four new patents continue to allow us to work with a limited number of pharmaceutical and medical device partners to help protect their investments in their markets with exclusive offerings.”
GLNT thanks the NIH for their continued support through the SBIR program, specifically the National Institute of Neurological Disorders and Stroke (R43NS043816–01A1, 2R44NS043816, R43NS074627, and 7R43NS065554), National Center on Minority Health and Health Disparities (R44MD004049), and National Institute on Aging (R43AG0347081). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Great Lakes NeuroTechnologies[ http://www.glneurotech.com ] is committed to pioneering innovative biomedical technologies to serve research, education, and medical communities, improving access to medical technology for diverse populations, and positively impacting quality of life for people around the world. Kinesia and KinesiaU are trademarks of Great Lakes NeuroTechnologies Inc. of Independence, OH.
Cariss Simmerman 216-361-5410 csimmerman@GLNeuroTech.com